KATHERINE MORSE: Open Payments
NPI 1386371326 · PROVO, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,551 in 210 payments from 19 companies in 2025. Trend: 2023 $1,120 · 2024 $2,654 · 2025 $3,551
Food & beverage: $3,551
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 63 | $997 |
| Janssen Biotech, Inc. | 23 | $443 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $356 |
| Madrigal Pharmaceuticals | 11 | $268 |
| PFIZER INC. | 27 | $259 |
| Aimmune Therapeutics, Inc. | 17 | $242 |
| Gilead Sciences, Inc. | 8 | $211 |
| Ardelyx, Inc. | 9 | $159 |
| Celltrion USA Inc. | 7 | $138 |
| GENZYME CORPORATION | 6 | $123 |
Products named: RINVOQ, TREMFYA, ENTYVIO, REZDIFFRA, DUPIXENT, SKYRIZI, XELJANZ, IBSRELA.
Industry payments across UT — which companies pay providers there.
